Skip to main content

Table 1 Change in HDL-c and HDL subclass in breast cancer patients

From: Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?

Study Patient enrolled High Density Lipoproteins
[134] N = 48 early-stage cancerous breast tumour patients
N = 40 non-cancerous breast tumour patients
HDL-c in breast cancer patients vs. non-cancerous patients
[135] N = 83 breast cancer patients (Stage I-IV)
N = 83 healthy patients
HDL-c in Stage IV breast cancer patients vs. healthy patients
[136] N = 58 breast cancer patients
N = 105 healthy patients
No change in HDL-c vs. healthy patients
[132] N = 30 breast cancer patients
N = 30 healthy patients
HDL-c, HDL2 and HDL3 vs. healthy patients, an effect more pronounced for HDL-2 (-41%) than HDL-3 (-8%)
[131] N = 56 postmenopausal breast cancer patients (Stage II-IV)
N = 44 healthy patients
HDL-c, HDL2 and HDL3 vs. healthy patients
Furthermore, advancement of disease affects lipid profile where,
HDL-c in Stage IV breast cancer patients vs. Stage II breast cancer patients
[137] N = 90 breast cancer patients
N = 103 healthy patients
HDL-c in breast cancer patients vs. healthy patients
[138] N = 100 breast cancer patients (Stage I-IV)
N = 50 healthy patients
No change in HDL-c in breast cancer patients vs. healthy patients
[139] N = 17 postmenopausal breast cancer patients
N = 30 postmenopausal healthy patients
No change in HDL-c in breast cancer patients vs. healthy patients
[128] N = 125 breast cancer patients (Stage I -IV)
N = 70 healthy patients
HDL-c breast cancer patients vs. healthy patients
[140] N = 100 pre- and postmenopausal breast cancer patients
N = 100 healthy patients
No change in HDL-c in breast cancer patients vs. healthy patients
[127] N = 120 breast cancer patients
N = 60 healthy patient
No change in HDL-c vs. healthy patients
[141] N = 60 pre- and postmenopausal breast cancer patients
N = 60 healthy patients
No change in HDL-c vs. healthy patients
[142] N = 249 early stage breast cancer patients
N = 154 healthy patients
HDL-c in breast cancer patients ≤ 50 years old vs. healthy patients
HDL-c in breast cancer patients ≥ 50 years old vs. healthy patients
[133] N = 56 breast cancer patients (Stage I-II)
No healthy patients included as controls
Large HDL subfractions associated with breast tumours expressing the progesterone receptor
[143] N = 150 breast cancer patients
N = 75 healthy patients
Unchanged HDL-c vs. healthy patients
[144] N = 1054 breast cancer patients
N = 2483 healthy patients
HDL-c in breast cancer patients < 60 years old vs. healthy patients
Unchanged HDL-c in breast cancer patients > 60 years old vs. healthy patients
  1. HDL-c High-density lipoprotein-cholesterol, vs. Versus